2023
DOI: 10.1016/j.tranon.2023.101623
|View full text |Cite
|
Sign up to set email alerts
|

MNRR1 is a driver of ovarian cancer progression

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
1

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 32 publications
0
2
0
Order By: Relevance
“…RNA sequencing: RNA sequencing of CTGF knockout (KO) and wild-type (WT) R182 cells were performed by GENEWIZ LLC (South Plainfield, NJ, USA) as described previously [18]. Differential gene expression analysis comparing R182-CTGFKO cells to WT R182-WT cells was performed by GENEWIZ LLC using the DESeq2 package [19].…”
Section: Methodsmentioning
confidence: 99%
“…RNA sequencing: RNA sequencing of CTGF knockout (KO) and wild-type (WT) R182 cells were performed by GENEWIZ LLC (South Plainfield, NJ, USA) as described previously [18]. Differential gene expression analysis comparing R182-CTGFKO cells to WT R182-WT cells was performed by GENEWIZ LLC using the DESeq2 package [19].…”
Section: Methodsmentioning
confidence: 99%
“…The significance of CHCHD2 extends to various diseases. It has been implicated in cancers (i.e ., induction) [ 32 , 33 ], Parkinson’s disease (i.e. , mutations) [ 34 ] and mitochondrial encephalomyopathy (i.e ., repression).…”
Section: Introductionmentioning
confidence: 99%